STERIS (NYSE:STE) Releases Earnings Results, Misses Expectations By $0.01 EPS

STERIS (NYSE:STE) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01), Zacks reports. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS updated its FY 2025 guidance to 9.050-9.150 EPS.

STERIS Stock Performance

Shares of STERIS stock opened at $220.97 on Thursday. The firm has a market capitalization of $21.81 billion, a P/E ratio of 50.45 and a beta of 0.84. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS has a 52 week low of $197.82 and a 52 week high of $248.24. The firm’s 50 day moving average is $212.33 and its two-hundred day moving average is $224.59.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be issued a $0.57 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.03%. STERIS’s payout ratio is currently 52.05%.

Insider Activity

In other news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.14% of the company’s stock.

Analyst Upgrades and Downgrades

STE has been the topic of several research reports. JMP Securities reissued a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. Piper Sandler raised their price target on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Stephens reiterated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. Finally, StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average price target of $263.75.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.